News
-
Aptar Pharma has announced a deal with French biotech Aceso Therapeutics related to development of Aceso’s ACT-101 antisense oligonucleotide for the treatment of cystic fibrosis. According to Aptar, its subsidiary Nanopharm will provide development services… Read more . . .
-
Inhaler testing specialist Copley Scientific has announced the launch of its new Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX. The company launched Version 1 of Inhalytix+, a subscription-based cascade impactor software package, in August 2025. The TPK… Read more . . .
-
According to Milestone Pharmaceuticals and Everest Medicines, the Chinese National Medical Products Administration has approved Everest’s NDA for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia. Etripamil. Everest acquired development, manufacturing, and commercialization rights… Read more . . .
-
Drug delivery specialist Nemera has announced the launch of a new bidose nasal spray platform called DuoSpray that is intended for delivery of systemic drugs, including CNS therapies. The company says that the customizable intranasal… Read more . . .
-
According to United Therapeutics, the FDA has accepted the company’s sNDA for Tyvaso treprostinil inhalation solution for the treatment of idiopathic pulmonary fibrosis. The FDA granted orphan drug designation to treprostinil for the treatment of… Read more . . .
-
Aurobindo Pharma announced that its newly-acquired US subsidiary Lannett has launched 100/50 mcg and 250/50 mcg strengths of a generic version of Advair Diskus fluticasone propionate / salmeterol xinafoate DPI in the US. Aurobindo notes that… Read more . . .
-
According to ENA Respiratory, the company has received AU$2.98 million in funding from the new Australian “national virtual incubator” Biointelect Venturer, with the funds going to support a Phase 1b study of ENA’s INNA-051 dry powder… Read more . . .
-
Milestone Pharmaceuticals has announced the initiation of the Phase 3 ReVeRA-301 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is expected to enroll about 150 patients who… Read more . . .
-
Silo Pharma gets notice of allowance for Canadian patent covering SPC-15 intranasal therapy for PTSD
According to Silo Pharma, the company has received a notice of allowance from the Canadian Intellectual Property Office related to a patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covering SPC-15… Read more . . .
-
According to Rein Therapeutics, the FDA has granted the company’s LTI-03 inhaled dry powder synthetic peptide Fast Track designation for the treatment of idiopathic pulmonary fibrosis. The company notes that the FDA previously granted orphan… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland